Using systematic reviews to inform NIHR HTA trial planning and design: A retrospective cohort Data collection, quality, and reporting

BMC Medical Research Methodology

Volumn 15, Issue 1, 2015, Pages

  Bhurke, Sheetal ^a   Cook, Andrew ^a   Tallant, Anna ^a   Young, Amanda ^a   Williams, Elaine ^a   Raftery, James ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Design; Health technology assessment; Primary outcome; Randomised controlled trials; Systematic reviews

Indexed keywords

HUMAN; LITERATURE; METHODOLOGY; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

HUMANS; NATIONAL HEALTH PROGRAMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; REVIEW LITERATURE AS TOPIC;

EID: 84952329028     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-015-0102-2     Document Type: Review

References (16)

1. Sutton AJ, Cooper NJ, Jones DR. Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol. 2009;9:29.
2. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156-65.
3. Clarke M. Doing new research? Don't forget the old. PLoS Med. 2004;1(2):e35.
4. Clarke M, Hopewell S, Chalmers I. Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010;376(9734):20-1.
5. Clarke M, Hopewell, S. Many reports of randomised trials still don't begin or end with a systematic review of the relevant evidence. J Bahrain Medical Soc. 2013, 24(3).
6. Clark T, Berger U, Mansmann U. Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ. 2013;346:f1135.
7. Habre C, Tramer MR, Popping DM, Elia N. Ability of a meta-analysis to prevent redundant research: systematic review of studies on pain from propofol injection. BMJ. 2014;348:g5219.
8. Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol. 2013;13:50.
9. National Institute for Health and Care Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. In: NICE Technology Appraisal Guidance No 34. London: National Institute for Health and Care Excellence; 2002.
10. Lewis R, Bagnall AM, Forbes C, Shirran E, Duffy S, Kleijnen J, et al. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. Health Technol Assess. 2002;6(13).
11. National Institute for Health and Care Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. In: NICE Technology Assessment Guidance 101. London: National Institute for Health and Care Excellence; 2006.
12. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess. 2007;11(2).
13. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE. 2011;6(7), e22003.
14. Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. J Clin Epidemiol. 2010;63(9):983-91.
15. Cooper NJ, Jones DR, Sutton AJ. The use of systematic reviews when designing studies. Clin Trials. 2005;2(3):260-4.
16. Adding Value in Research. http://www.nets.nihr.ac.uk/about/adding-value-in-research.